Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. The company is headquartered in New Brunswick, New Jersey and currently employs 138,100 full-time employees. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
The most recent EPS for Johnson & Johnson is $2.7, beating expectations of $2.69.
How did Johnson & Johnson JNJ's revenue perform in the last quarter?
Johnson & Johnson revenue for the last quarter is $2.7
What is the revenue estimate for Johnson & Johnson?
According to 16 of Wall street analyst, the revenue estimate of Johnson & Johnson range from $26.67B to $23.49B
What's the earning quality score for Johnson & Johnson?
Johnson & Johnson has a earning quality score of A-/71.4027. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Johnson & Johnson report earnings?
Johnson & Johnson next earnings report is expected in 2026-07-13
What are Johnson & Johnson's expected earnings?
Johnson & Johnson expected earnings is $23.86B, according to wall-street analysts.
Did Johnson & Johnson beat earnings expectations?
Johnson & Johnson recent earnings of $24.06B beat expectations.